IN
Indivior Pharmaceuticals Inc (INDV)
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic
$34.23
-0.23%
Mkt Cap $4.15B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 26, 2026 | $305.62M | $358.00M | +17.14% | $0.65 | $0.82 | +26.15% | — | — |
| Q4 2025 Oct 30, 2025 | $306.22M | $314.00M | +2.54% | $0.38 | $0.72 | +89.47% | — | — |
| Q3 2025 Jul 31, 2025 | $255.23M | $302.00M | +18.32% | $0.26 | $0.51 | +96.15% | — | — |
| Q2 2025 Apr 24, 2025 | $242.30M | $266.00M | +9.78% | $0.22 | $0.41 | +86.36% | — | — |
| Q1 2025 Feb 20, 2025 | $240.13M | $299.00M | +24.51% | $0.32 | $0.32 | +0.00% | — | — |
| Q4 2024 Oct 24, 2024 | $260.43M | $307.00M | +17.88% | $0.31 | $0.54 | +74.19% | — | — |
| Q3 2024 Jul 25, 2024 | $289.37M | $299.61M | +3.54% | $0.40 | $0.44 | +10.00% | — | — |
| Q2 2024 Apr 25, 2024 | $299.75M | $282.74M | -5.68% | $0.42 | $0.37 | -11.90% | — | — |
| Q1 2024 Feb 22, 2024 | $276.00M | $300.65M | +8.93% | $0.28 | $0.43 | +53.57% | — | — |
| Q4 2023 Nov 9, 2023 | $270.50M | $261.20M | -3.44% | $0.30 | $0.34 | +13.33% | — | — |
| Q3 2023 Jul 27, 2023 | $255.00M | $279.85M | +9.74% | $0.22 | $0.39 | +77.27% | — | — |
| Q2 2023 Apr 27, 2023 | $302.67M | $256.80M | -15.15% | — | $0.40 | — | — | — |
| Q4 2022 Dec 30, 2022 | $223.00M | $249.52M | +11.89% | — | -$1.38 | — | — | — |
| Q3 2022 Sep 29, 2022 | $217.00M | $220.24M | +1.49% | — | $0.27 | — | — | — |
| Q2 2022 Jun 29, 2022 | — | $214.44M | — | — | $0.33 | — | — | — |
| Q1 2022 Mar 30, 2022 | $219.00M | $202.72M | -7.43% | — | $0.27 | — | — | — |
| Q4 2021 Dec 30, 2021 | — | $222.67M | — | — | $0.25 | — | — | — |